Intuitive Surgical's Fifth Generation da Vinci System Receives CE Mark

04.07.25 15:45 Uhr

Werte in diesem Artikel
Aktien

124,25 EUR -1,20 EUR -0,96%

Indizes

7.696,3 PKT -58,3 PKT -0,75%

560,1 PKT -4,5 PKT -0,80%

5.288,8 PKT -54,3 PKT -1,02%

1.569,8 PKT -11,4 PKT -0,72%

3.519,6 PKT -17,6 PKT -0,50%

16.261,0 PKT -39,8 PKT -0,24%

5.851,4 PKT -43,1 PKT -0,73%

4.464,8 PKT -20,9 PKT -0,47%

Intuitive Surgical ISRG recently received CE mark approval for its latest da Vinci 5 Surgical System. This approval authorizes the system’s use across adult and pediatric patients in Europe for a broad range of endoscopic procedures, including abdominopelvic and thoracoscopic surgeries in urology, gynecology, and general laparoscopy. The approval marks a major regulatory step, expanding the clinical reach of Intuitive Surgical’s most advanced surgical platform to date.Building on the foundation of the da Vinci Xi Surgical System, the da Vinci 5 introduces enhanced integration, refined ergonomics, and next-generation capabilities to support surgeon precision and patient outcomes. With this approval, Intuitive Surgical strengthens its leadership in robotic-assisted surgery and continues to advance its mission to make surgery less invasive and more effective.Likely Trend of ISRG Stock Following the NewsFollowing the announcement, the company's shares traded flat until yesterday’s closing. Shares have risen 4.3% in the year-to-date period against the industry’s 7.5% decline. The S&P 500 has gained 5.4% in the same time frame.The CE mark approval for da Vinci 5 positions Intuitive Surgical to accelerate adoption across European markets, unlocking a sizable revenue opportunity in both system placements and recurring income from instruments, accessories, and service contracts. This expansion enhances Intuitive Surgical’s competitive moat in robotic-assisted surgery while aligning with hospital needs for surgical efficiency, workforce sustainability, and value-based care.ISRG currently has a market capitalization of $193.76 billion. It has an earnings yield of 1.45%, higher than the industry’s negative 2.88%. In the last reported quarter, ISRG delivered an earnings surprise of 5.85%.Image Source: Zacks Investment ResearchMore on ISRG’s da Vinci 5The da Vinci 5 Surgical System introduces over 150 design and performance enhancements, making it Intuitive Surgical’s most sophisticated multiport robotic-assisted platform to date. Among its core innovations are first-of-its-kind Force Feedback-enabled technology and the most realistic 3D vision system in the company’s portfolio, both engineered to improve surgical precision and patient outcomes.The system also features a newly designed ergonomic surgeon console to support long-term career sustainability. Surgeons gain greater autonomy with fingertip control of integrated components, while care teams benefit from a universal user interface and streamlined workflows. These upgrades are designed to enhance consistency, reduce setup time, and facilitate faster adoption across surgical teams.Intelligent computing is a key differentiator, with da Vinci 5 offering 10,000 times more processing power than earlier generations. The system integrates advanced sensors and software that deliver real-time, actionable insights to help surgeons quantify and improve their performance. This data-driven approach supports continuous improvement and performance benchmarking, particularly valuable as hospital systems seek to optimize surgical efficiency and outcomes.More on Intuitive Surgical’s da Vinci FamilyIntuitive Surgical’s da Vinci family of surgical systems comprises a range of multi-port and single-port platforms, designed to meet varying clinical and operational needs. The lineup consists of the da Vinci X and da Vinci Xi systems, widely adopted for their versatility and reliability, alongside the da Vinci SP system, which enables single-port access for narrow or deep anatomical areas.With the addition of da Vinci 5, the company now offers its most advanced platform, incorporating intelligent computing, ergonomic upgrades, and real-time data capabilities. This comprehensive portfolio allows hospitals and surgeons to choose solutions tailored to their procedural mix and workflow preferences, reinforcing Intuitive Surgical’s leadership in robotic-assisted surgery.Favorable Industry Prospects for ISRGPer a report by Grand View Research, the global surgical robots market size was estimated at $4.31 billion in 2024 and is projected to reach $7.42 billion by 2030, registering a CAGR of 9.42% from 2025 to 2030.Industry growth is driven by technological innovation, increasing investments from global and regional players, and a rise in chronic conditions and joint replacement procedures.ISRG’s Zacks Rank & Other Key PicksCurrently, ISRG carries a Zacks Rank #2 (Buy).Some other top-ranked stocks in the broader medical space are Hims & Hers Health, Inc. HIMS, Cencora, Inc. COR and Integer Holdings Corporation ITGR.Hims & Hers, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 36.5%. HIMS’ earnings surpassed estimates in two of the trailing four quarters, missed once and met in the other, the average surprise being 19.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Hims & Hers’ shares have surged 99.2% compared with the industry’s 37.1% growth in the past year.Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%.Cencora’s shares have rallied 23.9% against the industry’s 16.9% decline in the past year.Integer Holdings, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.Integer Holdings’ shares have gained 4.9% against the industry’s 13% decline in the past year.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Generation

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Generation

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu VINCI

Wer­bung

Analysen zu VINCI

DatumRatingAnalyst
01.07.2025VINCI BuyJefferies & Company Inc.
18.06.2025VINCI BuyUBS AG
13.06.2025VINCI BuyJefferies & Company Inc.
21.05.2025VINCI OverweightJP Morgan Chase & Co.
21.05.2025VINCI BuyUBS AG
DatumRatingAnalyst
01.07.2025VINCI BuyJefferies & Company Inc.
18.06.2025VINCI BuyUBS AG
13.06.2025VINCI BuyJefferies & Company Inc.
21.05.2025VINCI OverweightJP Morgan Chase & Co.
21.05.2025VINCI BuyUBS AG
DatumRatingAnalyst
09.12.2021VINCI Equal WeightBarclays Capital
21.10.2021VINCI Equal WeightBarclays Capital
20.10.2021VINCI HoldKepler Cheuvreux
09.09.2021VINCI Equal WeightBarclays Capital
12.07.2021VINCI Equal WeightBarclays Capital
DatumRatingAnalyst
03.08.2020VINCI VerkaufenDZ BANK
16.03.2020VINCI VerkaufenDZ BANK
24.04.2015Vinci SellS&P Capital IQ
05.02.2015Vinci SellS&P Capital IQ
23.09.2008Vinci verkaufenHamburger Sparkasse AG (Haspa)

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für VINCI nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen